Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2024 03:30 ET | Source: Vivet Therapeutics

Vivet Therapeutics to Present Key Findings on its Gene Therapy Program for Cerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting

Vivet Therapeutics to Present Key Findings on its Gene Therapy Program for Cerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting Gene therapy...
October 23, 2023 07:30 ET | Source: Vivet Therapeutics

Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress Paris, France, October 23, 2023 (GLOBE NEWSWIRE) – Vivet Therapeutics...
May 10, 2021 10:00 ET | Source: Vivet Therapeutics

Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting

Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting Compelling...
November 18, 2020 01:00 ET | Source: Vivet Therapeutics

Vivet Therapeutics y Pfizer Inc reciben autorización de la FDA para iniciar GATEWAY, ensayo clínico de fase 1/2 con VTX-801, la terapia génica de Vivet para la enfermedad de Wilson

Vivet Therapeutics y Pfizer Inc reciben...
November 18, 2020 01:00 ET | Source: Vivet Therapeutics

Vivet Therapeutics et Pfizer Inc. annoncent l’autorisation de la FDA de commencer l’étude de Phase 1/2 du VTX-801, GATEWAY, la thérapie génique expérimentale de Vivet pour la maladie de Wilson

...
November 18, 2020 01:00 ET | Source: Vivet Therapeutics

Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease

Vivet Therapeutics and Pfizer...